Watch Now: ETF Edge on Reshoring Trends, Weight Loss Drugs and More

CNBC21minutes ago

Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2

Seeking AlphaJul 1 08:30

Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report

Seeking AlphaJun 30 03:44

Amgen Is Maintained at Buy by Argus Research

Amgen Is Maintained at Buy by Argus Research

Dow JonesJun 28 01:57

Argus Research Maintains Buy on Amgen, Raises Price Target to $340

Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.

BenzingaJun 28 01:47

Amgen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 8.83% Argus Research $300 → $340 Maintains Buy 06/14/2024 6.27% RBC Capital $328 → $332 Maintai

BenzingaJun 28 01:46